{"disease":{"id":"gram-negative-bacterial-infections","name":"Gram-Negative Bacterial Infections","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"cefiderocol","indication_name":"Gram-Negative Bacterial Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fetroja","generic_name":"CEFIDEROCOL","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":"300","mechanism":"Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04917380","title":"The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06135350","title":"Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":234,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT05171257","title":"Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit","phase":"","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Methodist Health System","has_results":false},{"nct_id":"NCT05210387","title":"Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections","phase":"NA","overall_status":"TERMINATED","enrollment_count":107,"lead_sponsor_name":"Hospital Moinhos de Vento","has_results":false},{"nct_id":"NCT04861922","title":"Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"The Third Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT04215991","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Shionogi","has_results":false},{"nct_id":"NCT03160040","title":"A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting","phase":"","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)","has_results":false},{"nct_id":"NCT07503600","title":"The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT04335539","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Shionogi","has_results":true},{"nct_id":"NCT05639647","title":"Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07070375","title":"Pharmacokinetics and Safety of HRS-8427 in Healthy Volunteers and in Patients With Impaired Renal Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06086626","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Shionogi","has_results":false},{"nct_id":"NCT03182504","title":"A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04785924","title":"Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}